Regeneron wins EU nod for alternative Libtayo dose (REGN:NASDAQ)


Regeneron Pharmaceuticals (REGN) announced on Tuesday that the European Commission approved a more convenient dosing regimen for its cancer therapy, Libtayo, that will cut patients’ clinic visits and potentially halve their infusion times.

The decision greenlights a higher 700 mg



Source link

3 reasons to think twice before buying a new Fire TV Stick

Maura Higgins Among Favorites to Be Eliminated, Odds Say

Leave a Reply

Your email address will not be published. Required fields are marked *